Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 9/20 | 0.36 |
| ▸ | RAB9A | P51151 | 9/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | MAPT | P10636 | 7/20 | 0.36 |
| ▸ | TP53 | P04637 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.36 |
| ▸ | RELA | Q04206 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23987189 | 0.90 | CYP1A2 (0.35) | CYP1A2CYP2A6NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8227728 | 0.85 | CNR1 (0.39) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL8179979 | 0.85 | CYP1A2 (0.44) | CYP1A2CYP2A6NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31125665 | 0.81 | CA12 (0.43) | HSD17B10 | |
| SCHEMBL28590491 | 0.81 | CA12 (0.43) | HSD17B10 | |
| SCHEMBL13547932 | 0.80 | ESR1 (0.37) | ALDH1A1KDM4EHPGD | |
| SCHEMBL8253214 | 0.80 | HTR1B (0.40) | RAB9A | |
| SCHEMBL23978603 | 0.80 | PLK1 (0.36) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL24439367 | 0.79 | NPC1 (0.38) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL22965748 | 0.75 | HTR1B (0.37) | NPC1RAB9AALDH1A1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030878-B2 | Substituted indole ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023125935-A1 | BENZOPYRIDINE DERIVATIVE REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-11420973-B2 | Amide substituted indole compounds useful as TLR inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210070751-A1 | SUBSTITUTED INDOLE ETHER COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200331920-A1 | AMIDE SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | PROTIX B.V. (NL) | 2020-10-22 | — | — | US | disclosed |
| US-10280149-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20160368905-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LABORATORIES | 2016-12-22 | — | — | US | disclosed |
| WO-2008063669-A1 | HETEROBICYCLIC MATRIX METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063670-A1 | HETEROBICYCLIC MATRIX METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063671-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2007139860-A2 | HETEROBICYLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007139856-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007079199-A2 | SUBSTITUTED BIS-AMIDE METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, HOLDING, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ADAMTS4, ADAMTS1, ADAMTS5 | CYP1A2 3491/4885CYP2A6 2750/4885NPC1 3130/4885 |
| US-11420973-B2 | Amide substituted indole compounds useful as TLR inhibitors | TLR9, TLR1, TLR7 | CYP1A2 3365/4885CYP2A6 3376/4885NPC1 3480/4885 |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | CHRNA2, ACACA, CHAT | CYP1A2 234/4885CYP2A6 594/4885NPC1 139/4885 |
| US-10280149-B2 | Therapeutic compounds and uses thereof | KDM1B, KDM6B, KDM2B | CYP1A2 2538/4885CYP2A6 2951/4885NPC1 1175/4885 |
| US-20160368905-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | MAVS, ZC3HAV1, EIF2AK2 | CYP1A2 3713/4885CYP2A6 2395/4885NPC1 424/4885 |
| US-20230322770-A1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | TLR9, TLR3, TLR1 | CYP1A2 4622/4885CYP2A6 4269/4885NPC1 1121/4885 |
| US-20200331920-A1 | AMIDE SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | TLR9, TLR1, TLR7 | CYP1A2 3426/4885CYP2A6 3480/4885NPC1 3604/4885 |
| US-20180022727-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, KDM6B, KDM2B | CYP1A2 2538/4885CYP2A6 2951/4885NPC1 1175/4885 |
| US-20210070751-A1 | SUBSTITUTED INDOLE ETHER COMPOUNDS | TLR7, TLR8, TLR1 | CYP1A2 1157/4885CYP2A6 1404/4885NPC1 3064/4885 |
| US-12030878-B2 | Substituted indole ether compounds | TLR7, TLR8, TLR1 | CYP1A2 1157/4885CYP2A6 1404/4885NPC1 3064/4885 |
| US-20070155739-A1 | Substituted bis-amide metalloprotease inhibitors | MMP13, MMP9, ADAMTS13 | CYP1A2 352/4885CYP2A6 468/4885NPC1 2317/4885 |
| US-20080021024-A1 | Metalloprotease inhibitors | MMP2, MMP9, MMP3 | CYP1A2 212/4885CYP2A6 550/4885NPC1 1618/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | CYP1A2 763/4885CYP2A6 615/4885NPC1 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.